[Marrow transplantation in leukemia-recent trends].
Due to progress in conventional chemotherapy 50-60% of children with acute leukemia can be cured today. Despite these good results, however, 40-50% eventually will relapse and die. Other therapeutic modalities are therefore needed. Transplantation of bone marrow from an HLA-identical sibling offers this possibility. Initiated a decade ago as last therapy for end stage disease patients marrow transplantation is a well tolerated therapy today with well defined risks. In adults, marrow transplantation is clearly superior to conventional chemotherapy if performed early. The incidence of severe Graft-versus-Host-Disease, the major complication of marrow transplantation is much less after early transplantation and Cyclosporin-A, a new immunosuppressive agent further reduces severity of Graft-versus-Host-Disease. Since all complications are less in younger patients marrow transplantation is the therapy of choice for a child with leukemia having an HLA-identical sibling donor.
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D002648:Child; D003524:Cyclosporins / Q000627:therapeutic use; D006087:Graft vs Host Reaction; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D012306:Risk; D013997:Time Factors
D003524:Cyclosporins
Neue Entwicklungen in der allogenen Knochenmarkstransplantation bei Leukämien.